Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1Dermatologic 1

Conditions

Multiple Myeloma 809Precursor Cell Lymphoblastic Leukemia-Lymphoma 171Recurrence 141Neoplasms, Plasma Cell 111Lymphoma 93Leukemia 91Neoplasms 81Burkitt Lymphoma 57Vomiting 51Lymphoma, Non-Hodgkin 50Immunoglobulin Light-chain Amyloidosis 50Lymphoma, Large B-Cell, Diffuse 44Nausea 38Lymphoma, Mantle-Cell 38Prostatic Neoplasms 31Lymphoma, Follicular 30Hodgkin Disease 29Waldenstrom Macroglobulinemia 27Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 27Neoplasm Metastasis 26Leukemia, Lymphocytic, Chronic, B-Cell 26Carcinoma, Non-Small-Cell Lung 26Leukemia, Myeloid, Acute 25Breast Neoplasms 25Lung Neoplasms 23Amyloidosis 21Leukemia, Biphenotypic, Acute 18Lymphoma, B-Cell, Marginal Zone 17Lymphoma, Extranodal NK-T-Cell 16Smoldering Multiple Myeloma 15

Interventions

Amifostine 19Cisplatin 15Radiotherapy 13Etoposide 10Cyclophosphamide 9Carboplatin 8Paclitaxel 7Filgrastim 7Drug Therapy 5Cytarabine 5apatinib 4Methotrexate 4sodium thiosulfate 3Methylprednisolone 3Gemcitabine 3Docetaxel 3sargramostim 2pegfilgrastim 2glucarpidase 2etoposide phosphate 2denileukin diftitox 2camrelizumab 2Voriconazole 2Vincristine 2Social Determinants of Health 2Pyridoxine 2Peripheral Blood Stem Cell Transplantation 2Nivolumab 2Mitoxantrone 2Melphalan 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Drug-Related Side Effects and Adverse Reactions × Dexamethasone × Clear all
NCT00400946 2026-02-13

05-001: Treatment of Acute Lymphoblastic Leukemia in Children

Dana-Farber Cancer Institute

Phase 3 Completed
800 enrolled 22 charts
LymphoidOther hematologic neoplasm

Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Drug-Related Side Effects and Adverse Reactions

NCT00006345 2013-05-30

Dexamethasone Followed by Denileukin Diftitox in Treating Patients With Persistent or Recurrent T-Cell Lymphoma

National Cancer Institute (NCI)

Phase 2 Completed
DermatologicLymphoid

Lymphoma, Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡